Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Total Liabilities : $206.00 Mil (As of Sep. 2018)

View and export this data going back to 2000. Start your Free Trial

What is Keryx Biopharmaceuticals Total Liabilities?

Keryx Biopharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2018 was $206.00 Mil.

Keryx Biopharmaceuticals's quarterly Total Liabilities increased from Mar. 2018 ($171.73 Mil) to Jun. 2018 ($186.84 Mil) and increased from Jun. 2018 ($186.84 Mil) to Sep. 2018 ($206.00 Mil).

Keryx Biopharmaceuticals's annual Total Liabilities declined from Dec. 2015 ($171.75 Mil) to Dec. 2016 ($149.72 Mil) but then increased from Dec. 2016 ($149.72 Mil) to Dec. 2017 ($172.97 Mil).

Keryx Biopharmaceuticals Total Liabilities Historical Data

The historical data trend for Keryx Biopharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Keryx Biopharmaceuticals Total Liabilities Chart

Keryx Biopharmaceuticals Annual Data

Trend

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Total Liabilities

Get a 7-Day Free Trial

15.37

30.14

171.75

149.72

172.97

Keryx Biopharmaceuticals Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Total Liabilities	Get a 7-Day Free Trial															164.86	172.97	171.73	186.84	206.00

Keryx Biopharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Keryx Biopharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2017 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	45.42	+	(125	+	0.89400000000001
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	1.653	+	0)
	=	172.97

Total Liabilities	=	Total Assets (A: Dec. 2017 )	-	Total Equity (A: Dec. 2017 )
	=	158.872	-	-14.095
	=	172.97

Keryx Biopharmaceuticals's Total Liabilities for the quarter that ended in Sep. 2018 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.1	+	(147.302	+	0.767
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0.834	+	0)
	=	206.00

Total Liabilities	=	Total Assets (Q: Sep. 2018 )	-	Total Equity (Q: Sep. 2018 )
	=	151.784	-	-54.219
	=	206.00

Keryx Biopharmaceuticals Total Liabilities Related Terms

Thank you for viewing the detailed overview of Keryx Biopharmaceuticals's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Keryx Biopharmaceuticals (Keryx Biopharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Keryx Biopharmaceuticals Inc (NAS:KERX) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.keryx.com

Keryx Biopharmaceuticals Inc focuses on developing medicines to people with kidney diseases. The marketed product of the company is auryxia tablet, which is a iron based medicine.

Executives

Scott A Holmes	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS INC 1 MARINA PARK DR., 10TH FLOOR BOSTON MA 02210
Daniel Paul Regan	director	C/O INTERCEPT PHARMACEUTICALS, INC., 18 DESBROSSES ST., NEW YORK NY 10013
Jodie Pope Morrison	director, officer: Interim CEO	C/O TOKAI PHARMACEUTICALS, INC., ONE BROADWAY, 14TH FLOOR, CAMBRIDGE MA 02142
Mark J Enyedy	director	C/O FATE THERAPEUTICS, INC., 3535 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO CA 92121
Michael Thomas Heffernan	director	C/O CORNERSTONE THERAPEUTICS INC., 1255 CRESCENT GREEN DRIVE, SUITE 250, CARY NC 27518
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Michael W Rogers	director	C/O KERYX BIOPHARMACEUTICALS INC, ONE MARINA PARK DRIVE, BOSTON MA 02210
Baupost Group Gp, L.l.c.	10 percent owner	10 ST. JAMES AVENUE, SUITE 1700, BOSTON MA 02116
Baupost Group Llc/ma	director, 10 percent owner	10 ST JAMES AVE, SUITE 1700, BOSTON MA 02116
Seth A Klarman	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Greg Madison	director, officer: President and CEO	ONE MARINA PARK DRIVE LEXINGTON MA 02210
Brian Adams	officer: General Counsel and Secretary	750 LEXINGTON AVENUE, NEW YORK NY 10022
John P. Butler	director	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Sak Corp	10 percent owner	10 ST JAMES AVENUE, STE 1700, BOSTON MA 02116
Oliviero James F Iii	officer: Chief Financial Officer	C/O KERYX BIOPHARMACEUTICALS, INC., 750 LEXINGTON AVENUE, NEW YORK NY 10022